Subanesthetic ketamine infusions for suicide ideation in patients with bipolar and unipolar treatment refractory depression.

Autor: Kang MJY; Centre for Neuroscience Studies, Queen's University, Kingston, Ontario, Canada., Kulcar E; Moyano Psychiatric Hospital, Buenos Aires, Argentina., Chandrasena R; Chatham-Kent Health Alliance, Chatham, Ontario, Canada., Anjum MR; Chatham-Kent Health Alliance, Chatham, Ontario, Canada., Fairbairn J; Centre for Neuroscience Studies, Queen's University, Kingston, Ontario, Canada; Chatham-Kent Health Alliance, Chatham, Ontario, Canada., Hawken ER; Department of Psychiatry, Queen's University Medical School, Kingston, Ontario, Canada., Vazquez GH; Centre for Neuroscience Studies, Queen's University, Kingston, Ontario, Canada; Department of Psychiatry, Queen's University Medical School, Kingston, Ontario, Canada; International Consortium for Research on Mood & Psychotic Disorders, McLean Hospital, Belmont, MA, USA. Electronic address: g.vazquez@queensu.ca.
Jazyk: angličtina
Zdroj: Psychiatry research [Psychiatry Res] 2021 Feb; Vol. 296, pp. 113645. Date of Electronic Publication: 2020 Dec 16.
DOI: 10.1016/j.psychres.2020.113645
Abstrakt: We evaluated the effects of repeated subanesthetic ketamine infusions on suicidal ideation (SI) in patients with major depression. 82 subjects with treatment-resistant unipolar and bipolar depression completed a two-site open-label case-series of repeated (up to four weeks) infusions of ketamine (0.5 mg/kg). Ketamine produced a significant reduction in SI as early as one hour (71.1%) and up to 1-week post-infusion (60.4%), accompanied by a reduction in overall depressive symptoms which were maintained until the 4 th week. The observed anti-suicidal effect was independent of mood changes, as patients whose mood did not respond still exhibited significantly less SI than baseline.
(Copyright © 2020. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: